Results 81 to 90 of about 9,958,775 (335)

Inhibition of cyclin‐dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation

Molecular Oncology, EarlyView.
The proposed mechanism of action for the CDK12/13 inhibitor and cyclin K degrader, CT7439. CDK12/13 inhibition interrupts transcription elongation, leading to increased DNA damage that results in cell death. This agent is a potentially novel treatment option for patients with colorectal cancer. Created in BioRender. Cyclin‐dependent kinase (CDK) 12 and
Wylie K. Watlington, Divya L. Dayanidhi, Mohammad Zokaasadi, John B. Mantyh, Pelumi D. Olawuni, Gabrielle Rupprecht, Jeremy M. Force, Shannon McCall, Ashwani K. Bahl, David S. Hsu, Jason A. Somarelli   +10 more
wiley   +1 more source

Cytomegalovirus-Driven Adaption of Natural Killer Cells in NKG2Cnull Human Immunodeficiency Virus-Infected Individuals

Viruses, 2019
Expansion of natural killer (NK) cells expressing NKG2C occurs following human cytomegalovirus (HCMV) infection and is amplified by human immunodeficiency virus (HIV) co-infection.
Emilie M. Comeau, Kayla A. Holder, Neva J. Fudge, Michael D. Grant   +3 more
doaj   +1 more source

Development of antibody technology to identify natural killer cell surface antigens in Xenopus Laevis [PDF]

, 1999
Natural killer (NK)-like lymphocytes have recently been identified in thymectomised (Tx) Xenopus which are capable of spontaneous cytotoxicity towards the MHC- deficient, allogeneic thymus tumour cell line B(_3)B(_7).
Minter, Ralph
core  

In vitro and in silico modelling of ROS1‐positive non‐small cell lung cancer reveals fusion‐dependent tyrosine kinase inhibitor responses

Molecular Oncology, EarlyView.
Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Farhan Ul Haq, Marc Terrones, Felicia Rodrigues Fortes, Anne Schepers, Alessia Denis, Christophe Deben, Ken Op de Beeck, Guy Van Camp, Geert Vandeweyer   +8 more
wiley   +1 more source

Epigenetic silencing of the liver‐specific lncRNA LUNAR promotes liver cancer progression via NOTCH activation

Molecular Oncology, EarlyView.
LUNAR is a liver‐specific long noncoding RNA (lncRNA) that is highly expressed in normal liver but becomes epigenetically silenced in hepatocellular carcinoma through promoter hypermethylation. Loss of LUNAR is associated with NOTCH activation, epithelial–mesenchymal transition, and metastasis, whereas restoring LUNAR restrains metastatic progression ...
Se Ha Jang, Hyung Seok Kim, Geum Ok Baek, Moon Gyeong Yoon, Su In Lee, Jee‐Yeong Jeong, Ji Eun Han, Soon Sun Kim, Jae Youn Cheong, Jung Woo Eun   +9 more
wiley   +1 more source

Development of ISB 1442, a CD38 and CD47 bispecific biparatopic antibody innate cell modulator for the treatment of multiple myeloma

Nature Communications
Antibody engineering can tailor the design and activities of therapeutic antibodies for better efficiency or other advantageous clinical properties. Here we report the development of ISB 1442, a fully human bispecific antibody designed to re-establish ...
C. Grandclément, C. Estoppey, E. Dheilly, M. Panagopoulou, T. Monney, C. Dreyfus, J. Loyau, V. Labanca, A. Drake, S. De Angelis, A. Rubod, J. Frei, L. N. Caro, S. Blein, E. Martini, M. Chimen, T. Matthes, Z. Kaya, C. M. Edwards, J. R. Edwards, E. Menoret, C. Kervoelen, C. Pellat-Deceunynck, P. Moreau, M. L. Mbow, A. Srivastava, M. R. Dyson, E. A. Zhukovsky, M. Perro, S. Sammicheli   +29 more
doaj   +1 more source

Targeting the CXCR4 pathway using a novel anti-CXCR4 IgG1 antibody (PF-06747143) in chronic lymphocytic leukemia

Journal of Hematology & Oncology, 2017
Background The CXCR4-CXCL12 axis plays an important role in the chronic lymphocytic leukemia (CLL)-microenvironment interaction. Overexpression of CXCR4 has been reported in different hematological malignancies including CLL.
Manoj K. Kashyap, Carlos I. Amaya-Chanaga, Deepak Kumar, Brett Simmons, Nanni Huser, Yin Gu, Max Hallin, Kevin Lindquist, Rolla Yafawi, Michael Y. Choi, Ale-Ali Amine, Laura Z. Rassenti, Cathy Zhang, Shu-Hui Liu, Tod Smeal, Valeria R. Fantin, Thomas J. Kipps, Flavia Pernasetti, Januario E. Castro   +18 more
doaj   +1 more source

Antibody-dependent cell cytotoxicity synapses form in mice during tumor-specific antibody immunotherapy.

Cancer Research, 2011
Antibody-dependent cell cytotoxicity (ADCC) plays a critical role in monoclonal antibody (mAb)-mediated cancer therapy. ADCC, however, has not been directly shown in vivo but inferred from the requirement for IgG Fc receptors (FcγR) in tumor rejection in
P. Hubert, A. Heitzmann, S. Viel, André Nicolas, X. Sastre-Garau, P. Oppezzo, O. Pritsch, E. Osinaga, S. Amigorena   +8 more
semanticscholar   +1 more source

Studies on Antibody-Dependent Cell-Mediated Cytotoxicity of Sera from Patients with Ulcerative Colitis and Its Clinical Significance [PDF]

Several abnormalities in the immune system have been described in the pathogenesis of ulcerative colitis, although the mechanism of colonic epithelial destruction is not well elucidated yet.
Kadono, Yutaka
core   +1 more source

A Novel Fully Human Antitumor ImmunoRNase Targeting ErbB2-Positive Tumors [PDF]

, 2010
A second generation anti-ErbB2 ImmunoRNase, called Erb-hcAb-RNase, was obtained by the fusion of Erb-hcAb, a human compact anti-ErbB2 antibody, with human pancreatic ribonuclease (HP-RNase or RNase 1).
Borriello, Marianna
core   +1 more source